Vaccines fall within the remit of ANSM’s scope of action. They are medicinal products. The Agency is involved from the clinical trial phase. It then grants a national marketing authorisation (MA) according to the benefit-risk assessment. MAs may also be granted for the entire European Union by the European Commission, following a review by the European Medicines Agency (EMA) ANSM continues to carry out batch release procedures, surveillance of safety of use, and control over advertising aimed at the public and healthcare professionals.
